| Jump to: | Authorized Access | | | Attribution | | | Authorized Requests |
- Study Description
-
Important Links and Information
-
Request access via Authorized Access
- Instructions for requestors
- Data Use Certification (DUC) Agreement
- Talking Glossary of Genetic Terms
This study includes SSADDA (Semi Structured Assessment for Drug Dependence and Alcoholism) assessed subjects (mostly unrelated, but including some affected sibling pairs) recruited in the course of several substance dependence genetics projects. The sample includes 1,531 self-reported African-American (AA) subjects, 1,339 self-reported European-American (EA) subjects, and 2 who reported race as "unknown" or "missing".
- Study Design:
- Case-Control
- Study Type:
- Case-Control
- Family
- dbGaP estimated ancestry using GRAF-pop
- Total number of consented subjects: 2872
- Subject Sample Telemetry Report (SSTR)
-
Request access via Authorized Access
- Authorized Access
- Publicly Available Data
- Study Inclusion/Exclusion Criteria
Affected subjects were included on the basis of meeting DSM-IV criteria for opioid, cocaine, or alcohol dependence. Schizophrenia, bipolar affective disorder, or other major psychotic illness, and gross cognitive impairment were exclusion criteria in probands, although siblings of probands with these disorders were enrolled.
- Molecular Data
-
Type Source Platform Number of Oligos/SNPs SNP Batch Id Comment Whole Genome Genotyping Illumina HumanOmni1-Quad_v1-0_B 1051295 1049033 - Study History
This sample was collected in the course of three projects: studies focused on alcohol dependence genetics, and studies focused on cocaine and opioid dependence genetics. In the early stages of these studies, affected sibling pairs suitable for linkage analysis were collected, and a relatively small number of these families are included in the present sample. This sample and other overlapping and sub-samples were the basis of published linkage studies on alcohol, cocaine, opioid, and nicotine dependence; and GWAS studies of cocaine, opioid, alcohol, and nicotine dependence, as well as a "submitted" GWAS of cannabis dependence.
- Selected Publications
- Diseases/Traits Related to Study (MeSH terms)
- Authorized Data Access Requests
- Study Attribution
-
-
Principal Investigator
- Joel Gelernter, MD. Yale University School of Medicine, New Haven, CT, USA.
-
Co-Principal Investigator
- Henry R. Kranzler, MD. University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
-
Funding Sources
- Genetics of Opioid Dependence. National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, USA.
- Genome-Wide Study of Cocaine Dependence in Two Populations. National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, USA.
-
Principal Investigator